Despite the availability of global CKD management guidelines, adherence remains low, particularly with respect to the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is), which offer strong cardiorenal benefits particularly when initiated in a timely manner. This evidence concerns the gene SLC5A2 and chronic kidney disease.